<DOC>
	<DOC>NCT00621140</DOC>
	<brief_summary>To investigate efficacy, safety and tolerability of BI 1356 versus placebo</brief_summary>
	<brief_title>Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criteria: Male or female patients with type 2 diabetes and insufficient glycaemic control. Age 18 or over and not older than 80 years Exclusion criteria: Use of more than one oral antidiabetic agent within 10 weeks prior to informed consent, insulin, glitazones or GLP1 analogues within 3 months. Myocardial infarction, stroke or transient ischaemic attack within 6 months prior to informed consent.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>